Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of nirmatrelvir. It is given in a five-day course with three pills taken twice ...

Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Paxlovid, available since December 2021, reduced the COVID-19 death rate in high-risk patients by 73%, according to a study National Institutes of Health researchers released last year.

Paxlovid isn't the only antiviral medication for COVID-19. Merck’s Lagevrio is another available pill, though it's proven to be less popular in the U.S. than Paxlovid.

Dr. Astha Muttreja, a physician at the Stony Brook Medicine's post-COVID Clinic in Lake Grove, said there had been “cautious optimism” that Paxlovid would be a potential treatment method for ...

Those results are a blow to the millions of people living with the condition, which currently has no approved treatment or cure. Paxlovid has long been a source of hope for those with Long COVID.

Pfizer won't say. A Harvard study last year estimated the cost of producing generic Paxlovid at about $15 per treatment course, including manufacturing expenses, a 10% profit markup, and 27% in taxes.

Paxlovid is the most commonly prescribed at home treatment for COVID-19 in the U.S. It is approved to treat COVID in adults who are at risk of severe complications from the illness.

Paxlovid made no significant improvement to long COVID symptoms, including fatigue, brain fog and body aches. The finding “does not rule out” Paxlovid as a therapy, the researchers wrote.

A Harvard study last year estimated the cost of producing generic Paxlovid at about $15 per treatment course, including manufacturing expenses, a 10% profit markup, and 27% in taxes.

When Paxlovid was first authorized for emergency use in the U.S. in December 2021, it was free for anyone who needed it. Once the government stopped funding the treatment, Pfizer set a list price ...